Tonix Pharmaceuticals announces two poster presentations of TNX-102 SL

Tonix Pharmaceuticals announced two poster presentations at the American Society of Clinical Psychopharmacology, ASCP, Annual Meeting being held May 28-31, 2024 in Miami Beach, Fla. In the poster presentation titled, “Effect of Bedtime Sublingual Cyclobenzaprine on Pain, Sleep, Fatigue, and Cognition in Fibromyalgia-Type Long COVID: Results of a Double-Blind Randomized Proof-of-Concept Phase 2 Study,” TNX-102 SL showed a robust effect size of 0.5 in improving fatigue and showed consistent activity across secondary measures of sleep quality, cognitive function, disability and Patient Global Impression of Change, but did not meet the primary endpoint of multi-site pain reduction at Week 14.TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed. In the poster presentation titled, “Optimizing Acute Stress Reaction Interventions with TNX-102 SL – The OASIS Trial: Sustaining Civilian Performance Post-Trauma by Reduction of ASR and Prevention of ASD/PTSD,” TNX-102 SL will be evaluated for the reduction in severity of acute stress reaction and the frequency of acute stress disorder and posttraumatic stress disorder in civilians after a motor vehicle collision.